Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.
Publication
, Journal Article
Papautsky, EL; Carlson, M; Johnson, SM; Montague, H; Valero, L; Attai, DJ; Harvey, RD; Lyman, GH; Lustberg, M
Published in: Cancer Invest
August 2022
Despite the incorporation of trastuzumab biosimilars (to treat HER2-positive breast cancer) in clinical practice guidelines, gaps remain such as patient and clinician education. We hosted a webinar comprised of a panel of biosimilars experts, oncologists, pharmacist, infusion nurse, and a patient advocate. The outcomes of the webinar include audience responses to pre- and post-webinar questionnaires, educational benefits, real-time opportunities to ask questions, and a recording. Education needs to be tailored to the needs of both, patients and clinicians.
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
August 2022
Volume
40
Issue
7
Start / End Page
654 / 662
Location
England
Related Subject Headings
- Trastuzumab
- Oncology & Carcinogenesis
- Humans
- Female
- Breast Neoplasms
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Papautsky, E. L., Carlson, M., Johnson, S. M., Montague, H., Valero, L., Attai, D. J., … Lustberg, M. (2022). Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. Cancer Invest, 40(7), 654–662. https://doi.org/10.1080/07357907.2022.2093895
Papautsky, Elizabeth Lerner, Martha Carlson, Sheila Marie Johnson, Hannah Montague, Leeann Valero, Deanna J. Attai, R Donald Harvey, Gary H. Lyman, and Maryam Lustberg. “Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.” Cancer Invest 40, no. 7 (August 2022): 654–62. https://doi.org/10.1080/07357907.2022.2093895.
Papautsky EL, Carlson M, Johnson SM, Montague H, Valero L, Attai DJ, et al. Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. Cancer Invest. 2022 Aug;40(7):654–62.
Papautsky, Elizabeth Lerner, et al. “Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation.” Cancer Invest, vol. 40, no. 7, Aug. 2022, pp. 654–62. Pubmed, doi:10.1080/07357907.2022.2093895.
Papautsky EL, Carlson M, Johnson SM, Montague H, Valero L, Attai DJ, Harvey RD, Lyman GH, Lustberg M. Webinar as an Informational Resource on Trastuzumab Biosimilars: Planning, Promotion, Execution, and Evaluation. Cancer Invest. 2022 Aug;40(7):654–662.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
August 2022
Volume
40
Issue
7
Start / End Page
654 / 662
Location
England
Related Subject Headings
- Trastuzumab
- Oncology & Carcinogenesis
- Humans
- Female
- Breast Neoplasms
- Biosimilar Pharmaceuticals
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis